EUVIMEDEUVIMED entdecken
Crossref

Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells

Wenhui Zhao, Jianli Ma, Qingyuan Zhang, Han Zhang, Wenjie Ma, Shuo Li, Ying Piao, Shu Zhao, Shaochun Dai, Dabei Tang

Cell Biology International · 2024

DOI: 10.1002/cbin.12123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Biology International, 2024. Verfasst von Wenhui Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Ginsenosides. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tamoxifen (TAM) resistance poses a significant clinical challenge in human breast cancer and exhibits high heterogeneity among different patients. Rg3, an original ginsenoside known to inhibit tumor growth, has shown potential for enhancing TAM sensitivity in breast cancer cells. However, the specific role and underlying mechanisms of Rg3 in this context remain unclear. Aerobic glycolysis, a metabolic process, has been implicated in chemotherapeutic resistance. In this study, we demonstrate that elevated glycolysis plays a central role in TAM resistance and can be effectively targeted and overcome by Rg3. Mechanistically, we observed upregulation of 6‐phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase 3 (PFKFB3), a key mediator of glycolysis, in TAM‐resistant MCF‐7/TamR and T‐47D/TamR cells. Crucially, PFKFB3 is indispensable for the synergistic effect of TAM and Rg3 combination therapy, which suppresses cell proliferation and glycolysis in MCF‐7/TamR and T‐47D/TamR cells, both in vitro and in vivo. Moreover, overexpression of PFKFB3 in MCF‐7 cells mimicked the TAM resistance phenotype. Importantly, combination treatment significantly reduced TAM‐resistant MCF‐7 cell proliferation in an in vivo model. In conclusion, this study highlights the contribution of Rg3 in enhancing the therapeutic efficacy of TAM in breast cancer, and suggests that targeting TAM‐resistant PFKFB3 overexpression may represent a promising strategy to improve the response to combination therapy in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsGinsenosidesHumansFemaleTamoxifenAntineoplastic Agents, HormonalCell Line, TumorDrug Resistance, NeoplasmMCF-7 CellsGlycolysisGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

PFKFB3Rg3breast cancerglycolysistamoxifen

Substanzen

Tamoxifenginsenoside Rg3GinsenosidesAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Department of Ultrasound, Harbin Medical University Cancer Hospital, Harbin, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhao, W., Ma, J., Zhang, Q., Zhang, H., Ma, W., Li, S., Piao, Y., Zhao, S., Dai, S., & Tang, D. (2024). Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells. Cell Biology International. https://doi.org/10.1002/cbin.12123

Vancouver

Zhao W, Ma J, Zhang Q, Zhang H, Ma W, Li S, et al. Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells. Cell Biology International. 2024. doi:10.1002/cbin.12123

BibTeX
@article{Zhao2024,
  author = {Zhao, Wenhui and Ma, Jianli and Zhang, Qingyuan and Zhang, Han and Ma, Wenjie and Li, Shuo and Piao, Ying and Zhao, Shu and Dai, Shaochun and Tang, Dabei},
  title = {Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells},
  journal = {Cell Biology International},
  year = {2024},
  doi = {10.1002/cbin.12123}
}
Kostenlos starten →